COMMON INDIVIDUAL ANTIGENIC DETERMINANTS IN FIVE OF EIGHT BALB/c IGA MYELOMA PROTEINS THAT BIND PHOSPHORYL CHOLINE by Potter, Michael & Lieberman, Rose
COMMON  INDIVIDUAL  ANTIGENIC  DETERMINANTS  IN 
FIVE  OF  EIGHT  BALB/c  IGA  MYELOMA  PROTEINS 
THAT  BIND  PHOSPHORYL  CHOLINE 
BY MICHAEL POTTER, M.D., A~D ROSE  LIEBERMAN 
(From the Laboratory  of Cell Biology,  National Cancer Institute, and the Laboratory  of 
Immunology, National Institute of Allergy and Infectious Diseases, 
Bethesda,  Maryland 20014) 
(Received for publication 21 May 1970) 
Recently a large number of myeloma proteins derived from plasma cell tumors in- 
duced in the inbred BALB/c strain of mice have been tested for their ability to bind 
antigens. The first active protein found was a  serum IgA myeloma protein that pre- 
cipitated with the Pneumococcus C polysaccharide (1). Since this original report, seven 
more IgA proteins,  each derived from an independently induced tumor,  have been 
found which  precipitate  with  the  Pneumococcus C  polysaccharide  (2,  3,  and  this 
paper). Of the eight tumors, two originated in the laboratory of Dr. Melvin Cohn in 
La ]olla and six in our laboratory in Bethesda. 
The Pneumococcus C  polysaccharide is  a  complex antigen whose repeating  unit 
contains  galactose,  N-acetyl  galactosamine,  glucose,  2-acetamido-4-amino-2,4,6- 
trideoxyhexose, ribitol, phosphate  (4,  5)  and choline (6).  Recently Leon and Young 
have shown that the IgA myeloma proteins that bind the Pneumococcus C polysac- 
charide apparently all react with the same haptenic group on this antigen, as they have 
been able to inhibit precipitation of the Pneumococcus C polysaccharide by the IgA 
myeloma proteins with phosphoryl choline (7). 
We have  recently found another  antigen  derived  from a  species  of Lactobacillus 
aciclophilus that is also precipitated by these proteins.  This Lactobacillus  acidophilus 
species  is a common normal inhabitant of the BALB/c mouse's gastrointestinal tract. 
Interesting  questions involving a  functionally related  group of homogeneous im- 
munoglobulins derived from genetically similar  hosts  (inbred  BALB/c strain  mice) 
concern similarities  and differences  in structure among the individual proteins.  In a 
previous  report,  differences  in  two  proteins  in  this  group  were  reported  (2).  The 
question we wish to consider in this paper is whether  similarities  or even identities 
exist among any of the eight proteins in this group. 
Similarities  must ultimately be established by comparison of the primary structures 
of the light  and heavy polypepfide chains.  However,  another  sensitive  method for 
determining  similarities  among immunoglobulins of monoclonal origin  (M-proteins) 
is by demonstrating common individual antigenic specificities.  Many M-proteins have 
been shown to possess  individual or M-specific  determinants  (MSD) 1 that are unique 
1  Abbreviations used in this paper: MSD, M-specific  determinants;  PBS, phosphate-buffered 
saline, pH 7.4. 
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to  the  individual protein  used  for  immunization. Antisera  specific  for  individual 
homogeneous immunoglobulins (M-proteins) have been prepared for both human (8) 
and mouse (9,  10) M-proteins. 
Several series of functionally related M-proteins, the IgM cold hemagglutinins (11, 
12),  the IgG antistreptolysins (13)  in man, and the IgA antilipopolysaccharide pre- 
eipitins in the  mouse  (14)  have already been studied using myeloma or M-specific 
antisera.  Only with the  cold hemagglutinins have  common (cross-specific)  determi- 
nants been found on immunoglobulins of different cellular origin, and these occurred 
only on IgM proteins with cold hemagglutinating ability and not on IgM immuno- 
globulins (WaldenstrSm macroglobulins) lacking this property.  This result suggests 
that some cold agglutinins possess common structures. The serologic findings, however, 
indicated that  while individual specificities were  shared  by different IgM  cold  ag- 
glutinins, these proteins often differed by other eriteria, e.g. In antigen-binding speci- 
ficity or in their light chain subunits. Allotypie differences may further mask important 
individual  antigenic  specificities.  Whether  two  human  IgM-cold  agglutinins  are 
identical has neither yet been proven nor ruled out for cold hemagglutinins of inde- 
pendent cellular origin. 
In  this  study  we  have  prepared  homologous  antisera  to  each  of  the  eight 
IgA  myeloma  proteins  that  bind  phosphoryl  choline.  We  have  found  that 
three of the proteins have their own unique MSD and that five have a  common 
MSD  and thus far lack further individual characteristics.  These findings have 
suggested  the  possibility  that  the  five  IgA  proteins  (H8,  T15,  $63,  S107, 
and  M299)  are  extremely  similar.  Previously  Cohn  et  al.  have  reported  a 
common MSD  on the two IgA proteins $63  and S107  which originated at the 
Salk Institute (3). 
Materials and Method.s 
Source of Plasma Cell Tumors.--The  plasma cell tumors that produce IgA-class myeloma 
proteins with anti-phosphoryl choline-binding  activity were induced in BALB/c mice by the 
intraperitoneal injection of  mineral oil,  2,6,10,14-tetramethylpentadecane  (Pristane),  or 
7-N hexyloctadecane (Table I)  (15, 16). Each of these saturated hydrocarbons was injected 
in 0.5 ml amounts intraperitoueally three times when the mice were  2, 4,  and 6 months of 
age. Two of the rumors, $63 and S107, were induced by Dr. Melvin Cohn of the Salk Institute 
(1, 3) and sera from these mice were kindly provided by him for this study. 
Myeloma Protein Preparation.--The plasma cell  tumors were converted to the ascites form 
by intraperitoneal passage  of the tumor cells. Usually after one to two transfer generations the 
tumors produced the  ascites  in  the new hosts.  Groups of 20-30 mice were  inoculated with 
ascites tumor cells and when the ascites formed,  the fluid was harvested by paracentesis with 
a sterile 19 gauge needle. Usually two to three collections per mouse were possible. The ascites 
was diluted 1:2 with 0.005 lu sodium phosphate buffer containing 0.15 ~  NaC1 (PBS [phos- 
phate-buffered salineJ). The myeloma proteins were  then precipitated from diluted serum or 
ascites at 4°C by adding saturated ammonium sulfate. Some IgA myeloma proteins are readily 
precipitated at 33-37% saturation, others require 50% saturation with ammonium sulfate. 
The proteins as a rule were solubilized  in PBS and reprecipitated a second  time at 37-40% 
saturation in ammonium sulfate. The resolubilized precipitate was then dialyzed against water MICHAEL  POTTER  AND  ROSE  LIEBERMAN  739 
and the euglobulin fractions separated from the supernate. As a rule the euglobulin fractions 
contained aggregated polymers which usually can be resolubilized in 0.2-0.4  •  NH4HCO~. 
The euglobulin or water-soluble fractions were used as antigens in most of the studies. These 
fractions are identified as polymer fractions. 
Preparation of Fab.--Polymer  fractions were reduced in 0.03 M dithiothreitol (DTT)  for 
1 hr at room  temperature and  S-carboxy-methylated with 0.066 M iodoacetamide in 0.5 
tris(hydroxymethyl)aminomethane (Tris) chloride at pH  8.6 for 15 rain. This converts the 
polymer  to  a  monomeric  5.9  S  form.  Monomeric  IgA  was  digested  with  mercuripapain 
(Worthington Biochemical Corp.,  Freehold, N.  J.)  in PBS with a  protein to enzyme ratio 
16:1 for 1 hr at 37°C. DTT and EDTA were used to activate the papain and after digestion 
the mixture was treated with iodoacetamide to inactivate the essential sulfhydryl groups in 
the active site of papain. Agar gel electrophoresis and serologic studies revealed that Fc frag- 
ments (which carry the A 12, 1~, 14 allotypic markers) were destroyed by this procedure. Some 
Fab fragments were  further purified  by ion-exchange chromatography on  A-25 DEAE Se- 
phadex (Pharmacia Fine Chemicals, Uppsala, Sweden). 
Ultracentrifuge.--The M603  monomer  was  ultracentrifuged  in  the  Model L  analytical 
Spinco ultracentrifuge  (Beckman Instruments, Fullerton, Calif.)  at  a  concentration of  ap- 
proximately 10 mg/ml. Similarly, the Fab fragments of M603 and T15 were also run in the 
ultracentrifuge. The sedimentation coefficients of the monomeric IgA were found to be 5.9 
S20W. Sedimentation coefficients were determined on both chromatographically purified  Fab 
and dialyzed papain digests of IgA monomers. Both preparations consisted of a single peak in 
the ultracentrifuge with a sedimentation coefficient of 3.54 S. Following papain digestion some 
protein is converted to a relatively insoluble or aggregated form. A small 11 S peak was noted 
in the monomer preparations. 
Lactobacillus Antigens.--A  species of Laetobacillus acldophilus isolated  from  the normal 
intestinal flora of BALB/c mice in our colony contained an antigen that is also precipitated by 
the eight myeloma proteins used in this study. The antigen was originally isolated by tri- 
chloroacetic acid extraction of pressure-disrupted LactobaciUus acidophilus strain 4  by Mr. 
Charles K. Mills of the American Type Culture Collection. In the present experiments, this 
antigen was isolated from the species of Lactobacillus acidophilus by the method of Gotschlich 
and Liu (4). Essentially Lactobacilli were lysed in deoxycholate and then the treated organisms 
were heated in a boiling water bath for 30 mix. The antigen was extracted by precipitation 
with 95% ethyl alcohol. 
Inhibition  of Precipitation by Phosphoryl Choline and  Choline.--Antigenic  determinants 
identified in the Lactobacillus acidophilus antigen and Pneumococcus C  polysaccharide are 
probably similar since the precipitation of both antigens by the eight IgA myeloma proteins 
in this study is inhibited by phosphoryl choline. Quantitative inhibition of precipitation of 
Pneumococcus  C  polysaccharide  with  the  IgA  myeloma  proteins by  phosphoryl choline, 
choline, and other related compounds had been described originally by Leon and Young (7). 
In the present study we have employed a different method of inhibition of precipitation using 
agar gel methods and the Lactobacillus antigen instead of Pneumococcus C  polysaccharide. 
The IgA myeloma proteins were reacted with the LactobaciUus antigen in double diffusion 
agar gels.  After the precipitin lines had formed the gels were then immersed in solutions con- 
taining the inhibitors. Inhibition of precipitation was indicated by the disappearance of the 
precipitin line. 
Immunization of Inbred Mice with IgA Mydoma Proteins.--Each mouse was injected intra- 
peritoneally and subcutaneously in five areas including the two footpads, two axillary regions, 
and in one trunk area region with 75 jzg of the myeloma protein in 0.1 ml of equal parts of 
physiologic saline and complete Freund's adjuvant. The same injection in the identical areas 
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cedure was then repeated twice at 3-4 day intervals in the same areas with the myeloma protein 
alone. The mouse was first bled 4 wk after the first injection from the infraorbital sinus, and 
the serum was tested for precipitating antibody in double diffusion agar plates. If no precipi- 
tins were found,  similar injections were given with  the myeloma protein  alone at  weekly 
intervals. Most precipitins were usually detected in 4 wk. 
RESULTS 
Source and General Characteristics of the Plasma Cell Tumors.--The  source of 
the eight plasma cell tumors is given in Table 1. The two tumors,  $63 and S107, 
TABLE I 
Source of the Anti-Phosphoryl  Choline-IgA-Producing  Plasma ce,ll Tumors; 
L~ 'ht Chain Classes 
"~umor source 
of  myeloma 
protein* 
Material used 
to induce tumor 
Bayol F 
Bayol F 
Bayol F 
Pristane 
7 N-hexyloctadecane 
Bayol F 
Mineral oil 
Mineral oil 
Source,  reference 
Potter (2) 
Potter  (2) 
McIntire (2) 
Anderson (16) 
Anderson  (16) 
Potter:~ 
Cohn (3) 
Cohn (3) 
Location 
Bethesda 
La Jolla 
MOPC 167 
MOPC 299 
McPC 603 
TEPC  15 
HOPC 8 
MOPC 511 
S 63 
S 107 
Year 
1963 
1966 
1965 
1969 
1969 
196~ 
1967 
1967 
Light chain 
Class  Subclass 
K  iX 
K 
K  llI 
VI 
K  VI 
X 
K 
K 
* The myeloma protein will be designated by the first letter and number corresponding 
to the tumor source.  The  myeloma protein derived  from  MOPC  167  ~  M167.  Abbrevi- 
ation  of tumor source is based  on  material used  to induce tumors  (MOPC  =  mineral oil 
plasma cell)  or name of investigator that induced  tumor  (McPC  =  Mclntire plasma cell) 
or name of Institute where  tumor was induced  (S  =  Salk)  TEPC  is an  abbreviation for 
tetramethylpentadecane plasma cell tumor.  HOPC  is an abbreviation for 7-N-hexyloctadec- 
ane. 
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have  previously  been  described  by  Dr.  Melvin  Cohn  and  associates  (1,  3) 
and  we  have  used  them  only  in  serologic  studies,  i.e.,  the  tumors  have  not 
been  maintained  at  any  time  in  this  laboratory.  Three  of  the  tumors  in  our 
collection,  M167,  M299,  and  M603  have  been  previously  described  (2).  The 
MOPC  299 tumor lost its protein-producing ability in 1967 and all of the studies 
have  been  made  with  a  few  available  serum  samples  taken  during  its  early 
transplant  history.  Three  other tumors,  TEPC  15,  HOPC  8,  and  MOPC  511, 
are  described  here for the  first  time.  The  TEPC  15  and  HOPC  8  plasma  cell 
tumors  were  induced  in  separate  experiments  by  Dr.  Paul  Anderson  at  the 
National  Cancer  Institute.  Precipitation  with  the  Pneumococcus  C  polysac- 
charide  by  these myeloma proteins  was  discovered during  a  routine  screening MICHAEL  POTTER AND  ROSE  LIEBERMAN  741 
procedure against  a  series  of antigens.  The H8 and T15  are kappa  type IgA- 
producing  tumors not associated with  urinary protein  production.  The  MSll 
tumor,  by contrast,  has  a  rare  lambda  type light  chain  subunit  and  is  asso- 
ciated with Bence Jones proteinuria. 
Inhibitions  of Precipitation  by  Phosphoryl Choline and  Choline.--All  eight 
myeloma proteins  in  this  study  precipitated  with  the  Lactobacillus  antigen. 
Precipitation  of six of these proteins (those originating in our laboratory) with 
Lactobacillus antigen is shown (Fig.  1, left). Lines of identity are formed with 
five of the proteins  that have the kappa type light chains and a  line of partial 
identity  is  formed  with  the  511  (lambda  chain-containing  protein)  with  ad- 
jacent  kappa  type  IgA myeloma proteins.  In  the  inhibition  of precipitation 
FIG. 1.  Ouchterlony reactions showing inhibition of precipitation of Lactobacillus antigen 
LB4, with  phosphoryl  choline and  choline. Precipitin bands were allowed to develop over- 
night and then the gels were immersed in the inhibitor or solution. The control reaction before 
inhibition is Fig.  1, left;  Fig.  1, center  is the same gel after  its  being immersed in 0.001 
phosphoryl choline for about 60 rain. On the right is a third plate similar to the control Fig. 1, 
left, which was immersed in 0.01 M  choline chloride. The IgA myeloma proteins were polymer 
fractions for all of the proteins  except M299, for which whole serum was used; the concen- 
tration  of myeloma protein was 8 mg/ml for H8, T14, M603, and  M511. Concentration  for 
M167 was 24 mg per ml. The Lactobacillus antigen was a  1 mg/ml solution of an alcohol- 
precipitated  extract  from deoxycholate-lysed cells. The phosphoryl choline removes all the 
precipitins while the choline chloride removes only those to M167 and M511. 
studies,  the precipitin bands produced with the IgA myeloma proteins and the 
Lactobacillus  antigen  were  removed  by 0.001  ~  phosphoryl  choline  (Fig.  1, 
center).  With  the  0.01  M choline  chloride,  however,  the  precipitin  bands  of 
only  the  M167  and  M511  with  Lactobacillus  antigen  were  removed  (Fig.  1, 
right).  These results  agree with  the observations  of Leon and Young (7)  who 
demonstrated  that  the  M167  was  quantitatively  inhibited  by  free  choline 
chloride  in  contrast  to  M299,  M603,  and  T15,  which  were  not  inhibited  at 
these and 100-fold higher concentrations  of choline chloride. It  was concluded 
by Leon and Young that the M167 combining site did not require the presence 
of the phosphoryl group if the hapten was to be bound  (7). 
Specificity  of Antisera  Prepared to IgA  Myeloma  Proteins  that Bind  Phos- 
phoryl Choline.--Homologous  antisera were prepared to all eight myeloma pro- 
teins  (Table  II).  Inbred  strain  NH,  CE,  A/He,  and  AL mice  were  used  as 
recipients for immunizations. M-specific  antisera were successfully prepared  in 742  DETERMINANTS  IN  BALB/C IGA  MYELOMA  PROTEINS 
different  strains  by  immunization  with  the  same  myeloma protein.  Some  of 
these  same  antisera  also  identified  allotypic  specificities,  but  these  could  be 
made  specific for MSD  by absorption  with  the proper IgA Fc determinants. 
In this  study  only antisera  specific for MSD  were  employed. 
The  antisera  prepared  to M167,  M511,  and  M603  were specific for the  re 
spective  immunizing  antigen  (Fig.  2,  left).  Each  of  these  proteins  contained 
an  individual  determinant  or MSD  that  was  not found  on  any of the  other 
BALB/c IgA anti-phosphoryl choline proteins nor on over 120 other myeloma 
TABLE II 
Mydoma-Specific Antisera 
Number of mice 
Immunizing antigen  Recipient strain  Immunized  Producing antisera to 
MSD  Allotypic +  lVISD 
M511  NH  3  1  0 
CE  1  1  0 
AL  6  3  0 
M167  AL  4  3  1 
A/He  4  3  1 
M603  A/He  8  8  0 
CE  6  4  2 
M299  A/He  4  4  0 
AL  3  3  0 
T15  A/He  4  4  0 
AL  4  4  0 
H8  A/He  8  8  0 
$63  A/He  4  4  0 
NH  6  1  0 
S107  A/He  6  1  0 
NH  6  1  0 
proteins from the BALB/c mouse including 80 IgA proteins which were tested 
(Table III). 
The antisera prepared to H8, T15, $63,  S107, and M299 behaved differently 
for  each  one  of  these  antisera  precipitated  not  only  with  the  immunizing 
antigen but with all of the five myeloma proteins mentioned (Fig. 2, right). This 
was  a  particularly  surprising  result  since myeloma proteins  developed  in  two 
different laboratories  (e.g.  $63 and  S107 from Dr.  Cohn's laboratory and H8, 
T15,  and  M299  from  our  laboratory)  shared  a  common  MSD.  This  shared 
MSD was specific for only this group of proteins and was not found on a large 
series of other myeloma proteins tested (Table III). 
Localization of Myeloma-Specific Delerminants.--The  polymeric  IgA  mye- MICHAEL  POTTER  AND  ROSE  LIEBERMAN  743 
loma proteins were reduced in 0.03  ~  DTT at pH 8.9  and  S-carboxy-methyl- 
ated  with  iodoacetamide.  This  procedure  converts  the  polymers to  a  mono- 
meric 5.9  S form. Five of the myeloma proteins  (H8, T15,  M167,  M511,  and 
M603)  were  converted  to  5.9  S  and  tested  with  the  appropriate  MSD  anti- 
Fla.  2.  Ouchterlony reactions with  myeloma-specific  antisera. Antisera to myeloma pro- 
teins were prepared in A/He, except MSll which was in AL. Each antiserum was reacted with 
all eight of the IgA myeloma proteins that bind phosphoryl choline-containing antigens. The 
anti-M603, anti-M511, and anti-M167 antisera react  only with the respective immunizing 
antigen. The anti-T15, anti-H8,  and anti-M299 antisera all react  with five proteins: H8, 
M299, T15, $63, and S107. 
serum (Table IV). Each of the antisera precipitated with 5.9  S monomer (see 
example in Fig. 6). 
IgA myeloma proteins in the mouse are readily cleaved by papain into Fab 
and Fc fragments. When polymeric IgA molecules are used Fc fragments are 
obtained but when the monomeric (5.9  S)  form is digested,  the  Fc fragments 
are usually  destroyed.  In  the  present  experiments,  papain  Fab  fragments of 
H8, T15,  M167,  M511,  and M603  monomers were prepared.  These Fab frag- 744  DETERMINANTS  IN  BALB/C  IGA  MYELO~{A  PROTEINS 
ments  were  tested  with  an  anti-allotypic  IgA  antiserum  which  identifies  the 
A 1~ determinant  located  on  the  Fc part  of  the molecule.  This  antiserum  failed 
to  precipitate  with  the  Fab  fractions  indicating,  destruction  of  the  Fc  frag- 
ment  (Fig.  3). 
TABLE  III 
Summary of Agar Gel Precipitin  Reactions with Mydoma-Specific  Antisera 
Number of negative  Antisera  Anti-phosphoryl choline myeloma proteins  myeioma proteins tested 
Immunizing  Recipient  H8  T15  $63  S107  M167 M299  MSll  M603  lgA  IgF  IgG  IgH  antigen  strains 
M167  AL, A/He  +  --  84  19  11  15 
M51l  AL, CE  -  +  --  83  16  9  10 
M603  A/He, CE  --  +  84  19  11  15 
H8  A/He  +  +  +  +  --  +  --  --  77  16  9  10 
T15  A/He, AL  +  +  +  +  --  +  --  --  64  16  9  9 
M299  A/He, AL  +  +  +  +  --  +  --  --  77  15  7  9 
$63  A/He  +  +  +  +  --  +  --  --  60  15  8  9 
S107  A/He  +  +  +  +  --  +  --  --  77  15  7  9 
IgF  =  ")'1; IgG  =  "/2a; IgIt  =  3'2b. 
FIG. 3.  Ouchterlony  reactions  in  which  an  IgA  myeloma  allotypic  antisera  (anti-A  I~) 
was reacted with the IgA myeloma protein (Adj. PC-6A), normal serum from strain C57BR, 
and four different IgA myeloma Fab fragments.  Strong precipitin lines were obtained with 
the purified IgA myeloma protein 6A and the normal serum from C57BR, but not with the four 
Fab fragments. The allotbrpic  antiserum was prepared in  strain  DE  by immunization with 
MOPC 209 IgA myeloma protein. 
The  T15  and  M603  Fab  fragments  were  ultracentrifuged  to  determine 
homogeneity  (Fig.  4)  and  the ultracentrifuge  runs revealed  only a  single com- 
ponent  with  an  S20W  coefficient  of  3.54  S  (Fig.  4).  The  antisera  prepared  to 
M167,  MSll,  M603,  and  H8  did  not  precipitate  with  their  Fab  fragments 
(Table  IV).  It  has  been  noted  previously,  however,  that  Fab  fragments  in- 
hibit  precipitation  of  a  myeloma  protein  with  its  M-specific  antiserum  (9). 
This  inhibitory effect  is  demonstrated  in agar gels  by the failure  of  precipidn MICHAEL  POTTER  AND  ROSE  LIEBERMAN  745 
lines to extend into regions where Fab is in high concentration (Fig. 5).  The 
explanation for this phenomenon is that the Fab fragments are antigenically 
univalent  and  form  soluble  complexes  with  the  MSD  antisera,  and  these 
soluble  complexes  block  the  extension  of  precipitin  bands.  Fab  fragments, 
FIG.  4.  Ultracentrifuge  studies  of  T15  monomer  (upper)  and  M603  Fab  (lower).  The 
proteins were centrifuged at 59,780 rpm; the photographs were taken at 15, 31, 47, 63, and 79 
min. A  small shoulder in advance of the major peak is seen for the monomer in the 15- and 
31-min photograph. The $20 coefficient  for the monomer was calculated to be 5.92 S while the 
sedimentation coefficient for the Fab was 3.54 S. 
TABLE IV 
Absorption of Mydoma-Specific Antisera  with Fab Fragments 
IgA Polymer  Fab  5.9 S Monomer 
Antiserum 
to 
M167 
M603 
M511 
H8 
T15 
BALB/c IgA 
allotypes 
i Absorban 
--~--- 
M167 Fa] 
I M603 Fal 
M160 Fa] 
M6030 Fa] 
M5110 Fa] 
H8 Fab 
T15 0Fab 
H8 Fab 
, T15 Fab 
603 
+ 
however,  carry  the  M-specific  determinants;  absorption  of the  anti-H8  and 
anti-T15  M-specific antisera  with either H8  or T15  Fab  fragments  (Fig.  6) 
and  also  the  other  M-specific  antisera  with  their  respective  Fab  fragments 
completely removes all the precipitin reactions (Table IV). 
The antiserum to T15  was exceptional in that it precipitated with its Fab 
fragment as well as with the H8 Fab fragments (Table IV, Fig. 7, left). The pre- 
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Fla. 5.  Ouchterlony reactions. On the left the anti-H8 antiserum precipitates with the H8 
polymer, but not with the H8 Fab fragment. Note that the precipitin lines with the polymer 
extends into the well on the left but that the precipitin line does not extend an equal distance 
towards the source of the H8 Fab fragment, indicating inhibition of growth of the precipitin 
lines. The reaction on the right shows the failure of anti-H8 to precipitate with five different 
Fab fragments. 
Fio.  6.  Effect of absorption  of  anti-H8  and  anti-T15  antisera with T15  and  H8  Fab 
fragments respectively. Upper left and upper right show precipitation of five different polymer 
IgA myeloma proteins,  HS, T15, $63,  S107, and M299,  with the anti-H8 and anti-T15  anti- 
sera.  Also included is the ability of each of  these antisera to  precipitate with the T15 mono- 
mer (labeled T15  6  S).  Following absorption all precipitin lines were removed. 
those  produced  to  the  respective  IgA  polymer  or  monomer  (Fig.  7,  right). 
Furthermore,  even  though  a  precipitin  band  formed  with  anti-T15  and  T15 
Fab,  the Fab inhibition effect was still observed by shortening of the neighbor- 
ing precipitin  bands  (Fig.  7,  center).  These  results  indicate  that  the  anti-T15 MICHAEL  POTTER AND  ROSE LIEBERMAN  747 
antiserum  recognizes  two  topographically  different  determinants,  both  of 
which are present on the  H8 and T15  Fab fragments. These two sites are far 
enough  apart to permit simultaneous  binding  of the  Fab fragments by more 
than one antibody molecule  to form a  precipitate. This finding is of consider- 
able importance for it provides  additional evidence of the similarity of the H8 
and T15 proteins. 
Experiments  on  the  localization  of  the  M-specific determinants  to  specific 
chains or to conformations controlled by chain interactions are in progress. 
FIG.  7.  Ouchterlony reactions demonstrating characteristics of  the  anti-T15  myeloma- 
specific antiserum. On the left the anti-T15 antiserum precipitates with the H8 Fab fragment 
and the T15 Fab fragment but not with three other Fab fragments nor with C57BR normal 
serum. In the center the anti-T15 MSD antiserum precipitates  with five different  IgA myeloma 
proteins, H8, T15, $63, S107, and M299, and also the H8 Fab fragment. Note the inhibition 
of precipitation of the S107 and M299 lines in the regions where H8 Fab fragments are in high 
concentration. This produces a distorted hexagon. Reaction on the right shows the precipita- 
tion of anti-T15 with the T15 Fab, with T15 polymer, and with T15 5.9 S ((iS). Note again 
the striking inhibition of precipitation in  the regions where T15 Fab is most highly concen- 
trated. Note also the line of partial identity of the T15 Fab with the monomer and polymer 
precipitin lines. 
DISCUSSION 
The extraordinary specificity of the monodonal-specific antisera for the im- 
munizing  M-protein  antigen  suggests  that  the  anti-M167,  anti-M511,  and 
anti-M603  antisera  can precipitate  with  only one species of  immunoglobulin 
molecule.  The  same  degree  of  specificity  has  been  noted  for  anti-idiotypic 
antisera  (antisera  specific for  conventionally raised  antibodies)  (17-19).  One 
explanation for why anti-idiotypic antisera can be produced  is  that the  anti- 
body  used  in  immunization  in  fact  contains  a  predominating  homogeneous 
component  in  sufficient  concentration  to  induce  M-specific  antibodies  (19). 
It seems, therefore, safe to conclude that one characteristic of a  homogeneous 
or  monoclonal  immunoglobulin  is  its  unique  antigenicity.  The  specificity  of 
M-specific antisera  produced  in  mice  (homologous immunization)  appears to 748  DETERMINANTS  IN  BALB/c IGA  MYELOMA  PROTEINS 
be even greater than  that from heterologous immunization  since species dif- 
ferences are not involved in the immunization which could obscure M-specific 
determinants. 
The  antisera  that  precipitate  with  the  group  of  anti-phosphoryl  choline 
IgA M-proteins (H8, T15,  $63,  S107,  and M299)  are also highly specific for 
the group. These antisera also failed to precipitate with many other BALB/c 
IgA,  IgF,  IgG,  and  IgH  M-proteins  (Table  III).  This  common  or  shared 
specificity resembles the M-specificities assigned to single proteins. Two pos- 
sible  explanations  for the  common M-specific determinants  are  (a)  the  H8, 
T15,  $63,  S107,  and M299 proteins are  structurally identical or (0)  the H8, 
T15, $63, S107, and M299 share a common cross-specific antigenic determinant 
but  nonetheless  possess  structural  differences which  are  not  apparent.  We 
have been able to produce an M-specific antiserum to every IgA myeloma pro- 
tein  tested  thus  far,  and  for this  reason  the first explanation appears  more 
plausible to us at this time. 
Structural  studies  currently support  this  view.  In  experiments conducted 
in collaboration with  Dr. Leroy Hood, National  Cancer Institute,  (to be re- 
ported separately) on the amino-terminal sequences of the H8 and T15 light 
chains, as well as on tryptic and thermolysin peptide maps, indicate the iden- 
tity of H8 and T15 kappa light chains. Amino-terminal sequences and tryptic 
peptide maps of the M167 and M603 kappa chains reveal multiple differences 
from one another as well as from H8 and T15 (2, 20). Thus IgA M-proteins that 
bind phosphoryl choline antigens may be structurally very different from each 
other. The structural and antigenic similarities of H8 and T15 thus far demon- 
strated appear to predict that as the analysis progresses identity may indeed 
be established. Furthermore, the structural identities of H8 and T15 lead one 
to predict that the $63 and S107 proteins will also be identical to H8 and T15. 
Five  identical  myeloma  proteins  of  independent  cellular  origin  suggest 
that the same genes controlling light and heavy chains have been differentiated 
in  the  different  cells,  i.e.,  genetically  controlled  identical  antibodies  have 
developed  independently in  five different mice. 
Four  types  among  the  eight IgA  myeloma proteins  that  bind  phosphoryl 
choline are clearly different from one another. Each of these proteins  appears 
to resemble a single molecular species of immunoglobulin and hence might be 
analogous to homogeneous antibody. It is generally thought that the basis of 
the  immune  mechanism  depends  upon  selection of predetermined or  predif- 
ferentiated immunocytes by antigens which stimulate them to undergo further 
development and transformation to plasma cells.  Finding four different molec- 
ular species that bind the same hapten in different mice suggests that antigens 
containing  phosphoryl choline have  exerted a  specific selective  influence on 
the  total  population  of  immunocytes  in  BALB/c  mice  during  plasma  cell 
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in the mouse is of course the Lactobacillus antigen which is derived from the 
Lactobacillus  acidophilus  species  that is prevalent in the gastrointestinal tract 
of  BALB/c mice.  Other  sources  of  phosphory]  choline-containing antigens 
available in the mouse might be the intestinal helminths; it is known that ex- 
tracts  of  ascaris  also  contain  phosphoryl  choline-containing antigens  (15). 
A  third  potential  source  of  phosphoryl  choline-containing antigens  are  the 
lecithins and sphingomyelins which are found in membranes of animal tissues. 
Thus  the  source  of antigenic stimulation to precursors  of neoplastic plasma 
cells could then be postulated to be of autogenous origin. 
Lipids usually are not immunogenic. The production of anti-lipid antibodies 
depends upon coupling lipids to antigenic protein carriers (21).  However the 
bacterial antigens, such as Pneumococcus C polysaccharide and Lactobacillus 
antigen, may be highly immunogenic because of additional antigenic groupings, 
and may sensitize the host animal to the chemical group that is prevalent in 
the host, i.e., phosphoryl choline. Whatever the source of antigens that selects 
the cells that produce anti-phosphoryl choline type immunoglobulins must be 
generally distributed in mice to account for the frequent appearance of tumors 
that produce this type of specific immunoglobulin molecule. 
SUMMARY 
Eight IgA myeloma proteins derived from independently induced plasma- 
cytomas in genetically similar inbred BALB/c mice are functionally related 
by  their  binding  of  phosphoryl  choline-containing antigens  (Pneumococcus 
C  polysaccharide or Lactobacillus antigen). Each protein resembles  a  single 
species  of  immunoglobulin in  antibody.  The  proteins  are  characterized  by 
highly sensitive myeloma-specific antisera  prepared  by immunizing mice  of 
other inbred strains with the BALB/c myeloma proteins. Individual or mye- 
loma-specific determinants located on Fab fragments were found on three of 
the proteins  that were unique for  that protein  and did not react  with any 
other  IgA protein  among over  70  tested.  Remarkably, five of  the  proteins 
shared  two  common myeloma-specific determinants which  were  specific  for 
this group of five proteins. These results suggest that the five functionally and 
genetically related proteins sharing the same myeloma-specific determinants 
might also be structurally similar. 
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